EPISODE · Feb 2, 2021 · 1H 23M
What is FidoCure? | Ben Lewis #106
from Dog Cancer Answers · host Dog Podcast Network
For many years, DNA sequencing has been a first line option for diagnosing and treating many human cancers, in a treatment that is often referred to as, targeted therapy. Targeted therapy works by directly inhibiting the growth and replication of the cancer cells in certain types of tumors, and because of its targeted action it has shown high rates of tumor responsiveness in people. So, what happens when you take this science and apply it to dogs? Well, essentially the same thing, which is exciting and is exactly what we are talking about this week with Ben Lewis, the co-founder of FidoCure. Ben Lewis, the co-founder of FidoCure gives our listeners a deep lesson about genomic sequencing, as it relates to cancer causing DNA mutations. He shares the science behind FidoCure, the types of dog tumors that they’ve had the most success with, as well as how all this biotechnology and science could really help improve the standard of care and the prognosis of many types of cancers in humans and their dogs. Links Mentioned in Today’s Show: The Dog Cancer Survival Guide: Full Spectrum Treatments to Optimize Your Dog’s Life Quality and Longevity by Dr. Demian Dressler and Dr. Susan Ettinger. https://www.fidocure.com/ Link to the Hemangiosarcoma paper by Guannan Wang and Nicola Mason: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708669/ Link to the Science Exchange website: https://www.scienceexchange.com/ About Today’s Guest, Ben Lewis: Benjamin Lewis is an animal health visionary, proud pet parent, and former Olympic athlete. As CSO of the One Health Company, Ben is committed to advancing cancer cures for dogs. Formerly, Ben was the co-founder and CEO of 4Vets, the largest B2B distributor of animal health products in Brazil. Ben also represented the United States in the 2004 Olympics in Athens, Greece, where he served as captain of the K4. Ben studied bioengineering at Dartmouth College where he was inducted in the Dartmouth Hall of Fame (Wearer of the Green). In addition, Ben studied veterinary medicine at the University of Pennsylvania School of Veterinary Medicine, and Health Care Management at the Wharton School of Business. Connect with Ben by email: [email protected] Other Links: If you would like to ask a dog cancer related question for one of our expert veterinarians to answer on a future Q&A episode, call our Listener Line at 808-868-3200. Dog Cancer News is a free weekly newsletter that contains useful information designed to help your dog with cancer. To sign up, please visit DogCancerNews.com Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
For many years, DNA sequencing has been a first line option for diagnosing and treating many human cancers, in a treatment that is often referred to as, targeted therapy. Targeted therapy works by directly inhibiting the growth and replication of the cancer cells in certain types of tumors, and because of its targeted action it has shown high rates of tumor responsiveness in people. So, what happens when you take this science and apply it to dogs? Well, essentially the same thing, which is exciting and is exactly what we are talking about this week with Ben Lewis, the co-founder of FidoCure. Ben Lewis, the co-founder of FidoCure gives our listeners a deep lesson about genomic sequencing, as it relates to cancer causing DNA mutations. He shares the science behind FidoCure, the types of dog tumors that they’ve had the most success with, as well as how all this biotechnology and science could really help improve the standard of care and the prognosis of many types of cancers in humans and their dogs. Links Mentioned in Today’s Show: The Dog Cancer Survival Guide: Full Spectrum Treatments to Optimize Your Dog’s Life Quality and Longevity by Dr. Demian Dressler and Dr. Susan Ettinger. https://www.fidocure.com/ Link to the Hemangiosarcoma paper by Guannan Wang and Nicola Mason: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708669/ Link to the Science Exchange website: https://www.scienceexchange.com/ About Today’s Guest, Ben Lewis: Benjamin Lewis is an animal health visionary, proud pet parent, and former Olympic athlete. As CSO of the One Health Company, Ben is committed to advancing cancer cures for dogs. Formerly, Ben was the co-founder and CEO of 4Vets, the largest B2B distributor of animal health products in Brazil. Ben also represented the United States in the 2004 Olympics in Athens, Greece, where he served as captain of the K4. Ben studied bioengineering at Dartmouth College where he was inducted in the Dartmouth Hall of Fame (Wearer of the Green). In addition, Ben studied veterinary medicine at the University of Pennsylvania School of Veterinary Medicine, and Health Care Management at the Wharton School of Business. Connect with Ben by email: [email protected] Other Links: If you would like to ask a dog cancer related question for one of our expert veterinarians to answer on a future Q&A episode, call our Listener Line at 808-868-3200. Dog Cancer News is a free weekly newsletter that contains useful information designed to help your dog with cancer. To sign up, please visit DogCancerNews.com Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
What is FidoCure? | Ben Lewis #106
No transcript for this episode yet
Similar Episodes
No similar episodes found.